- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05256381
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
March 6, 2024 updated by: SOTIO Biotech AG
A Phase 2, Open-label, Single-arm, Multicenter Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced/Refractory Solid Tumors
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
320
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Richard Kapsa
- Phone Number: (+420) 2241 74448
- Email: kapsa@sotio.com
Study Locations
-
-
-
Anderlecht, Belgium, 1070
- Institut Jules Bordet
-
Brussels, Belgium, 1200
- Cliniques Universitaires Saint-Luc
-
Charleroi, Belgium, 6000
- Grand Hospital de Charleroi
-
Leuven, Belgium, 3000
- Universitair Ziekenhuis Leuven - Campus Gasthuisberg
-
Liège, Belgium, 4000
- Centre Hospitalier Universitaire de Liège
-
-
-
-
-
Brno, Czechia, 656 53
- Masarykuv onkologicky ustav
-
Hořovice, Czechia, 268 31
- Nemocnice Horovice
-
Olomouc, Czechia, 77900
- Fakultní Nemocnice Olomouc
-
-
-
-
-
Boulogne-Billancourt, France, 92100
- Hôpital Ambroise-Paré
-
Bourdeaux, France, 33000
- Merchant Logo Institute Bergonié
-
Caen, France, 14076
- Centre de Lutte Contre le Cancer
-
Marseille, France, 13005
- Hospital del la Timone
-
Nantes, France, 44093
- Centre Hospitalier Universitaire de Nantes
-
Nice, France, 06189
- Centre Antoine Lacassagne
-
Nice, France, 06202
- Hospital L'archet
-
Suresnes, France, 92150
- Hopital FOCH
-
Toulouse, France, 31059
- Institute Claudius Regaud
-
Villejuif, France, 94805
- Gustave Roussy
-
-
-
-
-
Batumi, Georgia, 6000
- High Technology Hospital MedCenter Ltd - Batumi
-
Kutaisi, Georgia, 4600
- Evex Hospitals- Kutaisi Referral
-
Tbilisi, Georgia, 0167
- Jerarsi Clinic
-
Tbilisi, Georgia, 0159
- Evex Hospitals - Caraps Medline
-
Tbilisi, Georgia, 0186
- Consilium Medulla Multiprofile Clinic
-
Tbilisi, Georgia, 0159
- New Vision University Hospital
-
Tbilisi, Georgia, 0112
- LLC Todua Clinic
-
Tbilisi, Georgia, 0160
- Tbilisi Institute of Medicine
-
Tbilisi, Georgia, 0186
- Evex Hospitals - Caucasus Medical Center
-
-
-
-
-
Budapest, Hungary, 1134
- Eszak-Pesti Centrumkorhaz - Honvedkorhaz
-
Győr, Hungary, 9023
- Petz Aladár Egyetemi Oktató Kórház - Győr
-
-
-
-
-
Brescia, Italy, 25123
- Azienda Socio Sanitaria Territoriale (ASST) degli Spedali Civili di Brescia
-
Meldola, Italy, 47014
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST
-
Napoli, Italy, 80131
- Instituto Nazionale Tumori IRCCS Fondazione G. Pascale
-
Piacenza, Italy, 29121
- Ospedale Guglielmo da Saliceto
-
Rome, Italy, 00168
- Fondazione Policlinico Universitario Agostino Gemelli
-
Siena, Italy, 53100
- Azienda Ospedaliera Universitaria Senese - L'ospedale Santa Maria alle Scotte
-
Sondrio, Italy, 23100
- Ospedale Civile Di Sondrio
-
Verona, Italy, 37134
- Azienda Ospedaliera Universitaria integrata Verona
-
-
-
-
-
Skorzewo, Poland, 60-185
- Pratia Poznan
-
Warszawa, Poland, 02-172
- MTZ Clinical Research Powered by Pratia
-
-
Wielkopolskie
-
Poznań, Wielkopolskie, Poland, 60-780
- Uniwersytecki Szpital Kliniczny w Poznaniu
-
-
-
-
-
A Coruña, Spain, 15006
- Hospital Teresa Herrera - Materno Infantil
-
Badalona, Spain, 08916
- Hospital Germans Trias i Pujol
-
Barcelona, Spain, 08035
- Hospital Universitari Vall d'Hebron
-
Barcelona, Spain, 08908
- Institut Catala d'Oncologia
-
Madrid, Spain, 28027
- Clinica Universidad de Navarra - Madrid
-
Madrid, Spain, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Spain, 28222
- Hospital Universitario Puerta de Hierro - Majadahonda
-
Madrid, Spain, 28050
- Hospital Universitario HM Sanchinarro
-
Madrid, Spain, 28027
- Clinica Universidad de Navarra - Pamplona
-
Valencia, Spain, 46010
- Hospital Clinico Universitario de Valencia
-
-
-
-
California
-
Whittier, California, United States, 90603
- Innovative Clinical Research Institute
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- University of Pittsburg Medical Center (UPMC) Hillman Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Participants with the following histologically or cytologically confirmed solid tumor indications and line of treatment:
- Non-small cell lung cancer (NSCLC).
- Colorectal cancer.
- Cutaneous squamous cell carcinoma (cSCC).
- Advanced hepatocellular carcinoma (not applicable in France).
- mCRPC.
- Ovarian cancer.
- Have measurable disease per RECIST 1.1. mCRPC participants with no measurable disease and only widespread bone disease must have a CTC count of ≥5 cells per 7.5 mL of blood.
- Availability of tumor tissue from a fresh biopsy at screening unless the biopsy cannot be obtained due to safety reasons or non-accessibility of the tumor site. If it is not possible to obtain a fresh biopsy, every effort should be taken to retrieve an archival biopsy. Archived, fixed tumor tissue may only be collected if taken preferentially after completion of the most recent systemic tumor therapy and within 12 months prior to the first dose of study treatment.
- Eastern Cooperative Oncology Group (ECOG) score 0-1.
- Have recovered from all AEs (except alopecia) due to previous therapies to grade ≤1 (excluding alopecia) or have stable grade 2 neuropathy.
Have adequate organ function as defined below:
Hematology:
- Absolute neutrophil count ≥1500/μL.
- Platelets ≥100 000/μL.
- Hemoglobin ≥9.0 g/dL .
- Renal function: Creatinine clearance as measured by glomerular filtration rate ≥30 mL/min using Cockcroft-Gault equation.
- Hepatic function: Alanine transaminase (ALT)/aspartate transaminase (AST) ≤2.5× upper limit of normal (ULN) and total bilirubin ≤1.5×ULN or direct bilirubin ≤ ULN in participants without liver metastasis. In participants with liver metastasis, ALT/AST ≤5×ULN is allowed but total bilirubin must be ≤2×ULN.
- Prothrombin time and activated partial thromboplastin time ≤1.5×ULN.
- Participants must not have active hepatitis B or hepatitis C infection.
- Adequate contraception must be applied in all women of childbearing potential (WOCBP) and in male participants.
Exclusion Criteria:
- Has received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti-programmed cell death ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor and was discontinued from that treatment due to a grade ≥3 AE.
- Prior exposure to agonists of interleukin (IL)-2 or IL-15.
Prior systemic anti-cancer therapies, including investigational agents:
- Less than 4 weeks for systemic chemotherapy and immuno-oncology therapies; and for tyrosine kinase inhibitors 4 weeks or 5 half-lives (whichever is shorter).
- Less than 4 weeks from major surgeries and not recovered adequately.
- Has received prior radiotherapy within 2 weeks of the start of study interventions or have had a history of radiation pneumonitis.
- NSCLC indication only: Received radiation therapy to the lung >30 Gy within 6 months.
- Has received a live or live-attenuated vaccine within 30 days.
Clinically significant cardiac abnormalities including prior history of any of the following:
- Cardiomyopathy, with left ventricular ejection fraction ≤ 50%.
- Congestive heart failure of New York Heart Association grade ≥2.
- History of clinically significant artery or coronary heart disease.
- Prolongation of QTcF >450 msec .
- Clinically significant cardiac arrythmia that cannot be controlled with adequate medication.
- Uncontrolled hypertension defined as systolic blood pressure >160 mmHg, diastolic blood pressure >110 mmHg.
- Prior allogeneic hematopoietic stem cell transplantation within the last 5 years.
- Prior allogeneic tissue/solid organ transplant.
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy.
- History of or serology positive for human immunodeficiency virus (HIV).
- Has a known additional malignancy that is progressing or has required active treatment within the past 5 years, except for basal cell carcinoma of the skin or carcinoma in situ that have undergone potentially curative therapy are not excluded.
- Has known active central nervous system metastases and/or carcinomatous meningitis, unless stable.
- Had severe hypersensitivity (grade ≥3) to pembrolizumab and/or any of its excipients.
- Has an active autoimmune disease that has required systemic treatment in the past 2 years.
- History of (non-infectious) pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease.
- Has an active infection requiring systemic therapy.
- Has any condition that might confound the results of the study or interfere with the participant's participation for the full duration of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nanrilkefusp Alfa and Pembrolizumab
Participants will be treated with 12 μg/kg of nanrilkefusp alfa on Day 1, Day 2, Day 8, and Day 9 of each 3-week cycle in combination with 200 mg pembrolizumab on Day 1 of each 3-week cycle.
|
Intravenous (IV) infusion via peripheral or central venous line.
Other Names:
Subcutaneous (SC) injection.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Objective Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)
Time Frame: Day 1 up to approximately 3 years
|
Day 1 up to approximately 3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants with a Treatment-emergent Adverse Event (TEAE)
Time Frame: Day 1 up to approximately 3 years
|
Day 1 up to approximately 3 years
|
Number of Participants with an Adverse Event of Special Interest (AESI)
Time Frame: Day 1 up to approximately 3 years
|
Day 1 up to approximately 3 years
|
Immune ORR (iORR) According to RECIST for immune-based therapeutics (iRECIST)
Time Frame: Day 1 up to approximately 3 years
|
Day 1 up to approximately 3 years
|
Best Overall Response (BOR) According to RECIST 1.1
Time Frame: Day 1 up to approximately 3 years
|
Day 1 up to approximately 3 years
|
Immune BOR (iBOR) According to iRECIST
Time Frame: Day 1 up to approximately 3 years
|
Day 1 up to approximately 3 years
|
Duration of Response (DoR) According to RECIST 1.1
Time Frame: Day 1 up to approximately 3 years
|
Day 1 up to approximately 3 years
|
Immune DoR (iDoR) According to iRECIST
Time Frame: Day 1 up to approximately 3 years
|
Day 1 up to approximately 3 years
|
Clinical Benefit Rate (CBR) According to RECIST 1.1
Time Frame: Day 1 up to approximately 3 years
|
Day 1 up to approximately 3 years
|
Immune CBR (iCBR) According to iRECIST
Time Frame: Day 1 up to approximately 3 years
|
Day 1 up to approximately 3 years
|
Progression-free Survival (PFS) According to RECIST 1.1
Time Frame: Day 1 up to approximately 3 years
|
Day 1 up to approximately 3 years
|
Immune PFS (iPFS) According to iRECIST
Time Frame: Day 1 up to approximately 3 years
|
Day 1 up to approximately 3 years
|
Time to Response (TtR) According to RECIST 1.1
Time Frame: Day 1 up to approximately 3 years
|
Day 1 up to approximately 3 years
|
Immune TtR (iTtR) According to iRECIST
Time Frame: Day 1 up to approximately 3 years
|
Day 1 up to approximately 3 years
|
Metastatic Castration-resistant Prostate Cancer (mCRPC) only: DoR as Assessed According to Prostate Cancer Clinical Trials Working Group 3 (PCWG3)-modified RECIST 1.1
Time Frame: Day 1 up to approximately 3 years
|
Day 1 up to approximately 3 years
|
mCRPC only: CBR as Assessed According to PCWG3-modified RECIST 1.1
Time Frame: Day 1 up to approximately 3 years
|
Day 1 up to approximately 3 years
|
mCRPC only: PFS as Assessed According to PCWG3-modified RECIST 1.1
Time Frame: Day 1 up to approximately 3 years
|
Day 1 up to approximately 3 years
|
mCRPC only: Circulating Tumor Cell (CTC) Count Conversion as Assessed According to PCWG3-modified RECIST 1.1
Time Frame: Day 1 up to approximately 2 years
|
Day 1 up to approximately 2 years
|
mCRPC only: Confirmed Prostate-specific Antigen (PSA) Decline of ≥50% as Assessed According to PCWG3-modified RECIST 1.1
Time Frame: Day 1 up to approximately 2 years
|
Day 1 up to approximately 2 years
|
mCRPC only: Time to Confirmed PSA Progression as Assessed According to PCWG3-modified RECIST 1.1
Time Frame: Day 1 up to approximately 2 years
|
Day 1 up to approximately 2 years
|
Number of Participants with Anti-drug Antibodies (ADAs)
Time Frame: Day 1 up to approximately 2 years
|
Day 1 up to approximately 2 years
|
Nanrilkefusp Alfa Concentration Profile at Various Timepoints
Time Frame: Cycle 1 Day 1 to Cycle 3 Day 1 (up to approximately 9 weeks, where each cycle is 3 weeks)
|
Cycle 1 Day 1 to Cycle 3 Day 1 (up to approximately 9 weeks, where each cycle is 3 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 21, 2022
Primary Completion (Estimated)
April 1, 2025
Study Completion (Estimated)
July 30, 2025
Study Registration Dates
First Submitted
February 8, 2022
First Submitted That Met QC Criteria
February 24, 2022
First Posted (Actual)
February 25, 2022
Study Record Updates
Last Update Posted (Actual)
March 8, 2024
Last Update Submitted That Met QC Criteria
March 6, 2024
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Endocrine Gland Neoplasms
- Genital Neoplasms, Male
- Liver Diseases
- Prostatic Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Colonic Diseases
- Intestinal Diseases
- Liver Neoplasms
- Intestinal Neoplasms
- Rectal Diseases
- Lung Neoplasms
- Neoplasms, Squamous Cell
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Genital Diseases, Female
- Prostatic Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma
- Carcinoma, Hepatocellular
- Colorectal Neoplasms
- Ovarian Neoplasms
- Carcinoma, Squamous Cell
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Pembrolizumab
Other Study ID Numbers
- SC104
- KEYNOTE-D13 (Other Identifier: Merck Sharp & Dohme)
- AURELIO-04 (Other Identifier: SOTIO Biotech AG)
- 2021-005774-25 (EudraCT Number)
- MK-3475-D13 (Other Identifier: Merck Sharp & Dohme)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
-
Edward KimBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
Clinical Trials on Pembrolizumab
-
University Medical Center GroningenCompleted
-
Incyte CorporationMerck Sharp & Dohme LLCCompletedMelanomaUnited States, France, Italy, United Kingdom, Spain, Belgium, Israel, Mexico, Japan, Canada, Netherlands, Sweden, Korea, Republic of, Australia, Russian Federation, Chile, Germany, Poland, Ireland, New Zealand, Denmark, Switzerland, South Africa
-
Merck Sharp & Dohme LLCCompletedMelanomaAustralia, South Africa, Spain, Sweden
-
Acerta Pharma BVMerck Sharp & Dohme LLCCompletedMetastatic Urothelial CarcinomaUnited States
-
HUYABIO International, LLC.Active, not recruitingNon Small Cell Lung CancerUnited States
-
Prof. Dr. Matthias PreusserUnknownPrimary Central Nervous System LymphomaAustria
-
Sichuan UniversityGeneplus-Beijing Co. Ltd.RecruitingNon-small Cell Lung CancerChina
-
Chinese University of Hong KongCompletedAcral Lentiginous MelanomaHong Kong
-
Samsung Medical CenterRecruitingMetastatic Non-Small Cell Lung CarcinomaKorea, Republic of